{
    "clinical_study": {
        "@rank": "95701", 
        "arm_group": [
            {
                "arm_group_label": "Stillen Tab.", 
                "arm_group_type": "Experimental", 
                "description": "administered three times daily for four weeks"
            }, 
            {
                "arm_group_label": "Mucosta Tab.", 
                "arm_group_type": "Active Comparator", 
                "description": "administered three times daily for four weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multicenter, active-controlled, randomized, double-blinded, paralleled group\n      clinical study to evaluate the efficacy of 4-week treatment with Stillen tab. in patients\n      with acute or chronic gastritis. Subject will receive Stillen tab or Mucosta tab., three\n      times a day for four weeks."
        }, 
        "brief_title": "A Study to Evaluate the Efficacy and of Stillen Tab. and to Demonstrate the Non-inferiority of Stillen Tab.", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Acute Gastritis", 
            "Chronic Gastritis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Gastritis", 
                "Gastritis, Atrophic", 
                "Acute Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age is over 20 years old, under 75 years old, men or women\n\n          -  Patients diagnosed with acute or chronic gastritis by gastroscopy\n\n          -  Patients with one or more erosions found by gastroscopy\n\n          -  Signed the informed consent forms\n\n        Exclusion Criteria:\n\n          -  Patients with peptic ulcer and gastroesophageal reflux disease\n\n          -  Patients administered with prokinetics, H2 receptor antagonists, proton pump\n             inhibitors, anticholinergic drugs or non-steroid anti-inflammatory drugs prior to\n             study in 2 weeks\n\n          -  Patients with surgery related to gastroesophageal\n\n          -  Patients with Zollinger-Ellison syndrome\n\n          -  Patients with any kind of malignant tumor\n\n          -  Patients administered with anti-thrombotic drugs\n\n          -  Patients with significant cardiovascular, pulmonary, heptic, renal, hemopoietic or\n             endocrine system primary disease\n\n          -  Women either pregnant or breast feeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "258", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01817556", 
            "org_study_id": "DA9601_Gas_IV"
        }, 
        "intervention": [
            {
                "arm_group_label": "Stillen Tab.", 
                "intervention_name": "Stillen Tab.", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Mucosta Tab.", 
                "intervention_name": "Mucosta Tab.", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 5, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "120-752"
                }, 
                "name": "Yonsei University Health System, Severance Hospital, IRB"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Active-controlled, Randomized, Double-blind Paralleled-group Clinical Trial to Evaluate the Efficacy of 4-week Treatment With Stillen Tab. in Patients With Acute or Chronic Gastritis", 
        "overall_official": [
            {
                "affiliation": "Yonsei University, Severance Hospital of Korea", 
                "last_name": "Yong Chan Lee, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "The Catholic University,  Yeouido St. Mary's Hospital of Korea", 
                "last_name": "Jin Il Kim, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Kyung Hee University Gangdong Hospital  of Korea", 
                "last_name": "Kwang Ro Joo, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Kangbuk Samsung Hospital of Korea", 
                "last_name": "Dong Il Park, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Konkuk University Hospital of Korea", 
                "last_name": "In Kyung Sung, M.D.,Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Konyang University Hospital of Korea", 
                "last_name": "Kyu Chan Huh, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Dongguk University Gyeongju Hospital of Korea", 
                "last_name": "Jung Il Suh, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Soon Chun Hyang University Bucheon Hospital of Korea", 
                "last_name": "Su Jin Hong, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Ajou University Hospital of Korea", 
                "last_name": "Jin Heung Kim, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Pusan National University Yangsan Hospital of Korea", 
                "last_name": "Dae Hwan Kang, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Inje University Sanggye Paik Hospital of Korea", 
                "last_name": "Tae Joo Jeon, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Inje University Haeundae Paik Hospital of Korea", 
                "last_name": "Tea Oh Kim, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Chungnam National Unviersity Hospital of Korea", 
                "last_name": "Hyun Yong Jeong, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Improvement rates of erosive gastritis (%)\n= (improved cases)/(total cases administered) * 100", 
            "measure": "Improvement rates of erosive gastritis", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01817556"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Healing rates of erosive gastritis (%)\n= (healed cases)/(total cases administered)*100", 
                "measure": "Healing rates of erosive gastritis", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "Symptoms improved level", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }
        ], 
        "source": "Dong-A Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dong-A Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}